FDA Pauses Trials Of Gilead’s HIV Combination Therapy After Triggering Safety Signal

Bloomberg Law (6/10, Langreth, Subscription Publication) reports Gilead Sciences announced the FDA had “placed on hold trials of a new experimental once-weekly HIV drug combination therapy after white blood cell counts dropped in some of the patients.” The studies involved taking two experimental HIV drugs, GS-1720 and GS-4182, together. Gilead explained the FDA suspended the trials due to a “safety signal” triggered by a decline in lymphocyte levels in some patients given the therapy.